You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Through the partnership, Strata will use its next-generation sequencing test to identify advanced cancer patients with mutations in the MAPK signaling pathway.
The Phase 0 trial will assess whether infigratinib can cross the blood-brain barrier to penetrate recurrent high-grade gliomas harboring FGFR genetic alterations.
The two companies will evaluate the efficacy of the combination in patients with ER-positive, HER2-negative, advanced breast cancer.
Within the partnership, Strata Oncology will use its StrataNGS test to identify patients with NRG1 gene fusions who may be eligible to enroll in a Phase II trial for the drug.
The Phase II trial in China will enroll 106 NSCLC patients with ROS1 fusions who have either never received a tyrosine kinase inhibitor or have received Xalkori.
A Phase II trial conducted in China also showed that the HER2-targeting TKI was safe and tolerable in patients with previously treated HER2-positive advanced NSCLC.
The Quantum Leap-sponsored I-SPY 2 trial will evaluate Byondis' antibody-drug conjugate SYD985 against standard of care for HER2-low, early-stage breast cancer.
The Phase Ib/II trial will assess dosage and antitumor activity of MEN1611 plus Erbitux for patients with PIK3CA-mutated, RAS and RAF wildtype advanced colorectal cancer.
The firms will jointly study the combination, and Sanofi will have an exclusivity period to negotiate the in-licensing of KN026, contingent on certain milestones.
The Phase II DESTINY-CRC01 and DESTINY-Gastric01 underscore the importance of HER2 testing in patients with colorectal cancers and gastric cancers, respectively.